ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

repotrectinib

Also written as “Repotrectinib”, “Oral repotrectinib (TPX-0005)” and “TPX-0005”.

Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Lymphoma · Sarcoma · Lymphoma, Follicular, led by Bristol-Myers Squibb.

Drug pageRepotrectinib: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 15, 20239 company-led studies, 3 open or runningNext primary completion: Feb 16, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb93 open or runningphase 3since Nov 15, 2023Mar 6, 2017Feb 16, 2027phase 3 · NCT06140836

Also a collaborator on its studies: Zai Lab.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2017First study: phase 2 study in SarcomaFirst studyNCT03093116 · 500 planned · United States, Australia, Belgium and more
  2. Dec 9, 2018Named repotrectinibINNProposed as its International Nonproprietary Name in WHO's List 120 · before, TPX-0005
  3. Sep 12, 2019Phase 2 study in LymphomaNCT04094610 · 75 planned · United States, Australia, Canada and more
  4. Sep 13, 2021Phase 2 study in Neoplasm MetastasisNCT05071183 · 9 enrolled · United States
  5. Mar 28, 20232 phase 1 studies in Neoplasm MetastasisNCT05828303, NCT05828277
  6. Nov 15, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836 · 190 enrolled · United States, Argentina, Austria and more
  7. Apr 3, 2024Phase 1 study in Lymphoma, FollicularNCT06352528 · 18 enrolled · United States
  8. Jun 25, 2024Phase 1 study in Healthy VolunteersNCT06493409 · 32 enrolled · United States
  9. Oct 30, 2025Phase 1 study in Healthy VolunteersNCT07223671 · 30 enrolled · United States

Ahead

  1. Feb 16, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06140836
  2. Feb 29, 2028Primary completion: phase 2 study in SarcomaNCT03093116

TargetBeta

“An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), ”NCIt, by rule
“Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor; NT-3 growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223671Healthy Volunteers · United States1CompletedFeb 19, 202630
NCT06493409Healthy Volunteers · United States1CompletedDec 7, 202432
NCT06352528Lymphoma, Follicular · United States1CompletedSep 16, 202518
NCT06140836Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingFeb 16, 2027190
NCT05828303Neoplasm Metastasis · United States, Australia, Brazil and more1WithdrawnJul 31, 20250
NCT05828277Neoplasm Metastasis · United States, Spain1WithdrawnAug 31, 20250
NCT05071183Neoplasm Metastasis · United States2TerminatedMar 1, 20239
NCT04094610Lymphoma · United States, Australia, Canada and more2RecruitingSep 30, 202675
NCT03093116Sarcoma · United States, Australia, Belgium and more2RecruitingFeb 29, 2028500

How it is read

Names in the registry

  • “Repotrectinib”, 4 entries
  • “Oral repotrectinib (TPX-0005)”, 2 entries
  • “TPX-0005”, 2 entries
  • “repotrectinib (TPX-0005)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.